A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
Brittany C. Michel(Broad Institute), Cigall Kadoch(Broad Institute), Michael Bocker(Foghorn Therapeutics (United States)), Nora Fortoul(Harvard University), Nathanael S. Gray(Stanford University), Caleb A. Lareau(Broad Institute), Matthew J. McBride(Broad Institute), Alfredo M. Valencia(Neurosciences Institute), Nazar Mashtalir(Broad Institute), Hayley Zullow(Broad Institute), Luis M. Soares(Foghorn Therapeutics (United States)), David Remillard(Dana-Farber Cancer Institute), Zachary M. McKenzie(Harvard University), Qianhe Zhou(Foghorn Therapeutics (United States)), Ho Man Chan, Seth H. Cassel(Broad Institute), James E. Bradner(Harvard University), Joshua Pan(Google (United States))
Cited by 435
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k